Small Cap-Cardiff Oncology Outlines Data From Discontinued Colorectal Cancer Trial, Stock Soars
Portfolio Pulse from Vandana Singh
Cardiff Oncology Inc (NASDAQ:CRDF) released data from its discontinued Phase 2 ONSEMBLE trial for second-line RAS-mutated metastatic colorectal cancer, showing efficacy of onvansertib. Despite discontinuing this trial to focus on a first-line treatment program, the company's stock soared by 37.60%. Cardiff Oncology had $75 million in cash at the end of 2023, expected to last until Q3 2025.
March 01, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardiff Oncology's stock soared by 37.60% after releasing data from its discontinued ONSEMBLE trial, showing efficacy of onvansertib in treating second-line RAS-mutated metastatic colorectal cancer.
The positive data from the discontinued ONSEMBLE trial, despite the shift in focus to a first-line treatment program, has significantly boosted investor confidence, leading to a sharp increase in CRDF's stock price. The company's strong cash position, expected to last until Q3 2025, further supports the positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100